Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    banners
    From bottlenecks to breakthroughs

    Human-centred strategies for faster study starts

    More than monitoring whitepaper
    More than monitoring

    How modern monitoring paradigms impact CRA roles

    digital globe network with icons
    Meeting requirements for Joint Clinical Assessments

    A planning guide for health technology developers

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    webinar
    Best practices in global flow cytometry quality control and harmonisation

    5 March 2026. Register today.

    webinar
    When patients lead: Breaking barriers in ultra-rare disease drug development

    3 March 2026. Register today.

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Social media

Social media

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

Showing 901 - 912 of 955 results for "*"

ICON Plc facebook post
ICON Plc logo
ICON Plc

Clinical data submissions require careful planning, consistency and a strong understanding of agency expectations. This whitepaper explores how regulatory teams can prepare unified materials that meet the requirements of...

5 Sep
1
ICON Plc facebook post
ICON Plc logo
ICON Plc

Each year, an estimated 400,000 children and adolescents develop cancer. Learn how ICON has been supporting research in #childhoodcancer and other #pediatric diseases. https://ow.ly/VXSx50WOVcN #ChildhoodCancer #Childh...

4 Sep
4
ICON Plc facebook post
ICON Plc logo
ICON Plc

If your company requires urgent rescue assistance – consider changing CRO. Impossible? Read the full story and learn how the ICON and Sponsor teams had to rapidly prepare for data cuts, while simultaneously transitionin...

4 Sep
2
ICON Plc facebook post
ICON Plc logo
ICON Plc

Biotechs and pharma companies in Asia Pacific face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is p...

4 Sep
2
ICON Plc facebook post
ICON Plc logo
ICON Plc

Join ICON experts live to learn how integrating COAs and DHTs in obesity trials supports: • Stronger regulatory alignment • Patient-centered outcomes • Better trial efficiency 📅 Oct 7 | 11am EDT | https://ow.ly/61yJ50...

4 Sep
1
ICON Plc facebook post
ICON Plc logo
ICON Plc

Symphony Health, an ICON plc company, are looking forward to Fierce Pharma Week (Sept 8–11) in Philadelphia. Visit us at booth #1320 to explore how our medical affairs, commercial, and promotional solutions help connect...

3 Sep
1
ICON Plc facebook post
ICON Plc logo
ICON Plc

Join ICON at the World CB & CDx Summit, 22–25 September in Boston. With deep scientific expertise, cutting-edge technologies, and seamless clinical trial integration, we translate exploratory research into real-world a...

3 Sep
1
ICON Plc facebook post
ICON Plc logo
ICON Plc

What does it take to lead with both heart and science? In the second installment of our employee spotlight series #BehindBiotech, we meet Dr. Mark Sorrentino - Vice President and Head of ICON’s Centre for Pediatric Clin...

3 Sep
5
ICON Plc facebook post
ICON Plc logo
ICON Plc

Biomarkers aren’t just supporting drug development, they’re driving it. This expert-led report produced in conjunction with Drug Target Review explores how biomarker science is advancing trial design, accelerating clinic...

3 Sep
1
ICON Plc facebook post
ICON Plc logo
ICON Plc

Faster access to life-saving therapies is within reach. Global regulators are working together to speed approvals for oncology and rare disease treatments—but navigating these pathways takes foresight and expertise. Ou...

2 Sep
3
ICON Plc facebook post
ICON Plc logo
ICON Plc

At #DPHARM2025 on 17 September at 3:40 PM, Faith Gabel will lead a pivotal session on evolving site networks beyond transactional execution toward delivering lasting value. Her insights will help clinical research profe...

2 Sep
4
ICON Plc facebook post
ICON Plc logo
ICON Plc

A sponsor of an Alzheimer's study sought ICON’s support with patient recruitment when the study had an unexpectedly high screen failure rate. Our teams screened 1,600+ patients in ten countries and completed recruitment ...

1 Sep
6
  • Previous
  • 1
  • …
  • 75
  • 76
  • 77
  • …
  • 80
  • Next
Filter by:

Filter by:

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?
  • All
  • Website
Popular search terms:
  • Biotech
  • Cell and Gene Therapies
  • Consulting
  • Early Clinical
  • Medical Device
  • Oncology
  • Rare & Orphan Diseases
  • Real World Evidence
  • Site & Patient Recruitment
  • Strategic Solutions
  • Regulatory Intelligence